Trials / Completed
CompletedNCT00804570
A Study for the Treatment of Alcohol Dependence
A Phase 2 Study of LY2196044 Compared With Placebo in the Treatment of Alcohol Dependence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 375 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence. Each subject will undergo a screening and assessment period (including medication washout) prior to randomization into a 16 week double blind treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2196044 | 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks |
| DRUG | placebo | once daily, orally, 16 weeks |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2008-12-09
- Last updated
- 2019-09-24
- Results posted
- 2017-02-03
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00804570. Inclusion in this directory is not an endorsement.